We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up
Read MoreHide Full Article
Israel-basedTeva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. In early Aug 2016, Teva acquired Allergan’s generics business – Actavis Generics and in Oct 2016 it acquired the latter’sAnda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S.
Teva’s earnings have surpassed expectations in two of the last four quarters and met the same in the other two, delivering an average positive surprise of 2.59%.
Teva Pharmaceutical Industries Limited Price and EPS Surprise
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s fourth quarter earnings (including equity compensation expenses), came in at $1.34 per share, beating consensus estimates of $1.32.
Revenues Beat: Teva posted revenues of $6.49 billion, marginally beating consensus estimates of $6.48 billion. Sales increased 33% year over year mainly due to the inclusion of Actavis revenues.
Key Statistics: Generic segment sales were $3.7 billion, up 44% year over year while Specialty segment sales were $2.2 billion, up 4%.
Lead branded product, multiple sclerosis drug Copaxone, posted worldwide sales of $1.01 billion, up 6%.
Keeps 2017 Outlook: Teva maintained the 2017 sales and earnings outlook it provided last month. Teva expects revenues in the range of $23.8–$24.5 billion and earnings in the band of $4.90–$5.30 per share in 2017.
Share Price Impact: Shares were up 4.4% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up
Israel-basedTeva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. In early Aug 2016, Teva acquired Allergan’s generics business – Actavis Generics and in Oct 2016 it acquired the latter’sAnda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S.
Teva’s earnings have surpassed expectations in two of the last four quarters and met the same in the other two, delivering an average positive surprise of 2.59%.
Teva Pharmaceutical Industries Limited Price and EPS Surprise
Teva Pharmaceutical Industries Limited Price and EPS Surprise | Teva Pharmaceutical Industries Limited Quote
Currently, TEVA has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Teva’s fourth quarter earnings (including equity compensation expenses), came in at $1.34 per share, beating consensus estimates of $1.32.
Revenues Beat: Teva posted revenues of $6.49 billion, marginally beating consensus estimates of $6.48 billion. Sales increased 33% year over year mainly due to the inclusion of Actavis revenues.
Key Statistics: Generic segment sales were $3.7 billion, up 44% year over year while Specialty segment sales were $2.2 billion, up 4%.
Lead branded product, multiple sclerosis drug Copaxone, posted worldwide sales of $1.01 billion, up 6%.
Keeps 2017 Outlook: Teva maintained the 2017 sales and earnings outlook it provided last month. Teva expects revenues in the range of $23.8–$24.5 billion and earnings in the band of $4.90–$5.30 per share in 2017.
Share Price Impact: Shares were up 4.4% in pre-market trading.
Check back later for our full write up on this TEVA earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>